1. Introduction

The asset sale of a distressed biotechnology company is a legal and commercial transaction in which a financially troubled biotech business sells some or all of its assets to another company, investor, pharmaceutical manufacturer, research institution, or insolvency purchaser.

Unlike a share sale, in which ownership of the company changes, an asset sale transfers specified assets. These may include patents, gene-editing technologies, clinical-trial data, biological samples, laboratory equipment, manufacturing facilities, regulatory approvals, research contracts, software, and intellectual property rights.

Asset sales are particularly significant in biotechnology because a company's most valuable assets may be intangible scientific discoveries rather than physical property. A financially distressed company might have valuable drug candidates or patented technologies despite being unable to pay its creditors.

The central legal question is:

How can a distressed biotech company sell valuable scientific assets to maximize creditor recovery while protecting patients, research participants, intellectual property rights, employees, and regulatory compliance?

The answer depends on insolvency law, contract law, intellectual property law, corporate governance, privacy law, biosafety regulation, and the jurisdiction in which the transaction takes place.

This explanation focuses primarily on the Indian legal framework, with comparative United States, United Kingdom, and Australian authorities where relevant.

2. Meaning and principal features

A distressed biotech asset sale generally arises when a company faces one or more of the following circumstances:

Inability to repay secured loans, suppliers, employees, or research partners.

Failure to obtain additional venture-capital or pharmaceutical-industry funding.

Termination or suspension of clinical trials.

Expiry of cash reserves before regulatory approval.

Loss of a major licensing or commercialization agreement.

Insolvency proceedings, liquidation, or a court-supervised restructuring.

Assets commonly involved

An important distinction is that selling an asset does not necessarily transfer every legal permission associated with that asset. A patent may be assignable, for example, while a clinical-trial authorization, personal-data processing right, or research-participant consent may require separate legal analysis.

3. Legal framework in India

A. Insolvency and Bankruptcy Code, 2016

The principal legislation is the Insolvency and Bankruptcy Code, 2016 (IBC). Its application depends on whether the company is undergoing a corporate insolvency resolution process (CIRP), liquidation, or a transaction outside formal insolvency proceedings.

The principal provisions include:

Section 18: Duties of the interim resolution professional, including taking control and custody of relevant assets.

Section 25: Duties of the resolution professional, including preservation of the corporate debtor's assets.

Section 29A: Restrictions on specified persons who are ineligible to submit resolution plans.

Section 30: Submission and consideration of resolution plans.

Section 31: Approval of a resolution plan by the adjudicating authority.

Section 35: Powers and duties of the liquidator, including realization of assets.

Section 52: Rights of secured creditors in liquidation.

Section 53: Statutory distribution waterfall for liquidation proceeds.

A biotech company's intellectual property must be valued and dealt with under the applicable insolvency process. The resolution professional or liquidator cannot simply assume that every patent, licence, research database, or biological material is freely transferable.

B. Sale methods and valuation

During liquidation, Regulation 32 of the IBBI (Liquidation Process) Regulations, 2016 has historically provided for different forms of asset sale, including standalone assets, sets of assets, parcels, and sales of a business as a going concern.

Regulation 33 generally addresses the mode of sale, ordinarily by auction, with specified circumstances in which private sale may be used.

Important current-law qualification: The IBBI amended the Liquidation Process Regulations in October 2025, including changes affecting going-concern sale provisions. Consequently, a transaction undertaken in 2026 must be checked against the regulations as currently in force rather than relying solely on the older text of Regulations 32 and 32A.

Mehta & Mehta Advisory

+1

For biotech assets, a proper valuation should separately consider:

Patent validity, remaining term and freedom to operate.

Clinical-stage and preclinical-stage drug candidates.

Probability of regulatory approval and commercialization.

Research reproducibility and the quality of trial data.

Existing licence royalties and milestone obligations.

Equipment condition, maintenance, and biosafety liabilities.

Restrictions on the transfer or future use of biological samples.

A low sale price does not necessarily establish illegality. However, a sale to an insider at an undervalue, a concealed transfer, or a transaction designed to defeat creditors may invite scrutiny under insolvency and avoidance provisions.

4. Important case laws

The following authorities provide principles relevant to distressed biotech asset sales. Some are general insolvency decisions rather than disputes involving biotechnology specifically; their relevance lies in the legal principles they establish.

Case 1: Innoventive Industries Ltd. v. ICICI Bank

Citation: (2018) 1 SCC 407, Supreme Court of India.

Facts and issue: The dispute concerned the relationship between the IBC and conflicting state legislation, and the operation of the insolvency framework following a corporate debtor's default.

Legal principle: The Supreme Court emphasized the statutory structure and overriding operation of the IBC where inconsistent laws apply, subject to the Code's provisions.

Application to biotech asset sales: A distressed biotech company cannot avoid applicable insolvency consequences merely by relying on a conflicting contractual arrangement or another legal regime. Asset sales must be structured consistently with the governing insolvency process.

Case 2: Swiss Ribbons Pvt. Ltd. v. Union of India

Citation: (2019) 4 SCC 17, Supreme Court of India.

Legal principle: The Court upheld the constitutional validity of major elements of the IBC framework and explained the distinction between resolution and liquidation, emphasizing the importance of preserving and resolving viable businesses.

Application: If a biotech company has valuable patents, drug-development programmes, or manufacturing capacity, a resolution that preserves the business may produce greater value than a fragmented liquidation. This is a commercial and legal consideration, not a guarantee that a going-concern sale must always be chosen.

Case 3: Arun Kumar Jagatramka v. Jindal Steel and Power Ltd.

Citation: (2021) 7 SCC 474, Supreme Court of India.

Facts and issue: The case considered the eligibility restrictions under Section 29A in the context of a scheme of compromise or arrangement for a company undergoing liquidation.

Legal principle: Ineligible persons cannot circumvent the IBC's restrictions through an alternative restructuring route where the statutory prohibition applies.

Application: A promoter who caused or was involved in the biotech company's financial distress cannot assume that liquidation permits an unrestricted repurchase of the company's assets. The precise restrictions depend on the proposed transaction and the applicable statutory provisions.

Indian Kanoon

+1

Case 4: Sundaresh Bhatt, Liquidator of ABG Shipyard v. Central Board of Indirect Taxes and Customs

Citation: (2023) 1 SCC 472, Supreme Court of India.

Facts and issue: The dispute involved the authority of customs officials over goods belonging to a company undergoing liquidation and the interaction between customs law and the IBC.

Legal principle: The Court clarified the respective roles of the customs authorities and the liquidator, including the limits on independent recovery action against assets subject to the insolvency process.

Application: If a biotech company holds imported laboratory equipment, bioreactors, reagents, or other goods subject to customs claims, the sale must account for the interaction between insolvency administration and the applicable customs regime. The case does not mean that every statutory customs liability automatically disappears upon sale.

Supreme Court

Case 5: Ms Visisth Services Ltd. v. S.V. Ramani

Citation: NCLAT, Company Appeal (AT) (Insolvency) No. 896 of 2020.

Legal issue: The case examined the consequences of a proposed sale of a corporate debtor as a going concern during liquidation and the obligations attached to a bidder's offer.

Application: A buyer of a distressed biotech business should identify clearly which assets and liabilities are included, what consideration must be paid, and which conditions must be satisfied. The label “going concern” should not be treated as a substitute for examining the actual sale terms and applicable law.

Indian Kanoon

+1

Case 6: Massachusetts Department of Unemployment Assistance v. OPK Biotech, LLC (In re PBBPC, Inc.)

Citation: 484 B.R. 860 (Bankr. D. Mass. 2013).

Facts: A distressed business sought bankruptcy-court approval for the sale of substantially all its operating assets to OPK Biotech, LLC. The sale order addressed liens, encumbrances, and potential successor liability.

Legal significance: The decision illustrates how a bankruptcy court may approve a transaction involving substantial operating assets and how the sale order can define the treatment of specified claims and liabilities.

Application to biotechnology: Where a biotech purchaser acquires patents, research equipment, manufacturing assets, or a drug-development programme, it must examine the scope of any court-approved sale and the limits of protections against successor liability. A contractual disclaimer or sale order should not be assumed to extinguish every regulatory, environmental, employment, or patient-related obligation.

Hall Approved — Free American Case Law

Case 7: In re Cybergenics Corp.

Citation: 226 F.3d 237 (3d Cir. 2000), United States Court of Appeals for the Third Circuit.

Facts: Cybergenics sold substantially all its assets in bankruptcy, including intellectual property and other business assets. A later dispute concerned the ability to investigate and pursue potential claims arising from earlier transactions.

Legal significance: The decision demonstrates that the sale and distribution of assets do not necessarily eliminate every cause of action connected with the debtor's pre-bankruptcy affairs.

Application to biotechnology: A buyer acquiring a patent portfolio or drug-development programme should distinguish between the assets purchased and the legal claims that may remain with the insolvency estate. Fraudulent-transfer claims, contractual disputes, and claims concerning earlier transactions require separate analysis.

Justia Law

Case 8: In re Watertech Holdings, LLC

Citation: 619 B.R. 324 (Bankr. D.S.C. 2020).

Facts: The bankruptcy court considered the sale of substantially all assets, including contract rights, intellectual property, goodwill, and associated documents.

Legal significance: The decision illustrates the use of court-supervised asset-sale procedures, bidding arrangements, notice, and approval of the sale transaction.

Application to biotechnology: An asset purchase agreement should identify the intellectual property and related rights being transferred with sufficient precision. Where several bidders are involved, a transparent process can support the commercial defensibility of the transaction.

FindLaw

+1

These United States bankruptcy decisions are comparative authorities, not binding precedents for Indian insolvency proceedings.

5. Intellectual property rights and patent transfer

Intellectual property is often the most valuable component of a biotech asset sale. A company may own a patent on a therapeutic molecule, gene-editing method, diagnostic platform, engineered microorganism, or manufacturing process.

Under Indian law, the Patents Act, 1970 governs patent assignments and licences. Section 68 is particularly relevant because assignments and licences relating to patents must satisfy its requirements concerning written instruments and registration to be valid.

The buyer should establish:

Whether the company is the actual patent owner.

Whether inventors or research institutions have competing ownership claims.

Whether security interests or prior exclusive licences exist.

Whether government-funded research creates additional conditions.

Whether the patent is valid, enforceable, and commercially useful.

Whether the technology infringes third-party intellectual property.

Copyright, trade secrets, databases, software, and proprietary research protocols may be governed by different legal rules. A patent assignment alone does not transfer every associated right.

Example

Suppose BioNova Ltd. develops a patented cancer therapy but becomes unable to pay its creditors. A pharmaceutical company offers ₹40 crore for the patent portfolio, laboratory records, and manufacturing know-how.

Before accepting the offer, the insolvency professional should determine whether:

The patents belong to BioNova or to a university collaborator.

The patents are already licensed exclusively to another manufacturer.

A lender holds a security interest over the intellectual property.

The clinical evidence can lawfully be disclosed and used by the purchaser.

The proposed transaction is commercially reasonable and procedurally valid.

If the patents are subject to an exclusive licence, the buyer's rights may be substantially narrower than the apparent ownership documents suggest.

6. Clinical-trial data, biological samples and patient protection

Biotech asset sales raise distinctive issues because research assets may contain information about identifiable individuals or biological materials collected under specific consent conditions.

Clinical-trial data

A buyer may need access to trial protocols, adverse-event reports, laboratory results, patient follow-up information, and regulatory correspondence.

The transfer must be evaluated under applicable privacy law, contractual confidentiality obligations, clinical-trial rules, and the terms of participant consent. In India, the Digital Personal Data Protection Act, 2023 and its applicable commencement provisions and rules must be considered alongside other relevant laws.

The transfer of a database does not automatically give the buyer unlimited authority to reuse identifiable patient information for new research or marketing.

Biological samples

Tissue samples, cell lines, DNA specimens, and engineered organisms require examination of:

Original consent and permitted research purposes.

Donor and institutional agreements.

Provenance and lawful collection.

Biosafety, storage, transport, and disposal requirements.

Any applicable restrictions on human biological materials.

An insolvency sale cannot lawfully expand consent or extinguish statutory protections simply because a purchaser pays for the research assets.

Regulatory approvals

A drug-development asset may include a regulatory dossier or an approval obtained from a competent authority. The buyer must verify whether the relevant authorization can be transferred, amended, or relied upon by the buyer and whether fresh applications, notifications, or approvals are required.

The commercial value of a drug candidate may decline sharply if the purchaser cannot lawfully continue the clinical trial or manufacture the product.

7. Avoidance of fraudulent and undervalued transactions

One of the most serious legal risks is the sale of valuable biotech assets at an artificially low price shortly before insolvency.

For example, a company might transfer a patent portfolio worth ₹100 crore to a promoter-controlled entity for ₹5 crore while leaving substantial creditors unpaid.

Depending on the facts, such a transaction may raise issues under Sections 43, 45, 49 and 66 of the IBC, concerning preferential transactions, undervalued transactions, transactions defrauding creditors, and fraudulent or wrongful trading.

The applicable requirements and remedies differ between these provisions. A transaction is not automatically unlawful merely because the company was distressed or the sale price was below an initial valuation.

A proper investigation should consider:

Whether independent valuation was obtained.

Whether the purchaser was related to the company or its promoters.

Whether the sale process was competitive and transparent.

Whether creditors were deliberately disadvantaged.

Whether the transaction complied with applicable approvals and disclosure requirements.

A court or tribunal may grant relief where the relevant statutory conditions for avoidance or other remedies are established.

8. Secured creditors and competing claims

Biotech assets are frequently financed through venture debt, secured lending, or intellectual-property-backed transactions.

A lender may hold security over patents, equipment, receivables, or shares in a subsidiary that owns the research assets. Consequently, the company may not be entitled to transfer all the assets free of existing encumbrances.

Under Sections 52 and 53 of the IBC, secured-creditor rights and the statutory distribution waterfall are important in liquidation. The precise treatment depends on the method chosen by the secured creditor and the applicable statutory requirements.

The purchaser should obtain a complete schedule of security interests and establish how each will be discharged, retained, or otherwise treated at closing.

9. Transaction structure: a practical legal checklist

The following sequence provides a useful framework for a distressed biotech asset sale.

Step 1 — Due diligence

Verify ownership, patents, licences, clinical data, biological samples, contracts, employee obligations, security interests, and regulatory status.

Step 2 — Valuation and sale authority

Obtain independent valuations where appropriate and determine whether board, creditor, insolvency professional, tribunal, or regulatory approvals are required.

Step 3 — Asset purchase agreement

Define the purchased assets, excluded assets, consideration, liabilities assumed, warranties, indemnities, closing conditions, and treatment of existing licences.

Step 4 — Scientific and regulatory safeguards

Verify the lawful transfer and continued use of trial data, samples, regulatory dossiers, manufacturing permissions, and biosafety systems.

Step 5 — Closing and distribution

Complete registrations, obtain required consents, address security interests, deliver the assets, and distribute proceeds according to the applicable insolvency framework.

10. Common legal disputes

11. Comparative perspective

The United States provides a particularly useful comparison because bankruptcy courts may approve asset sales under Section 363 of the US Bankruptcy Code, including sales free and clear of specified interests when the statutory requirements are met.

The In re PBBPC decision is especially relevant because the purchaser was OPK Biotech. It illustrates the importance of precisely defining the assets and protections contained in the bankruptcy sale order.

Hall Approved — Free American Case Law

In India, the analysis instead begins with the IBC, applicable IBBI regulations, the powers of the resolution professional or liquidator, the rights of secured creditors, and any necessary approvals under other laws. A US-style free-and-clear sale cannot simply be assumed to have the same effect under Indian law.

In Australia and the United Kingdom, the transaction must similarly be analyzed under their respective insolvency frameworks, intellectual-property laws, privacy regimes, and therapeutic-goods or medicines regulations.

12. Conclusion

Asset sales involving distressed biotechnology companies require more than an ordinary commercial transfer. Their legality depends on the relationship between insolvency procedure, ownership of scientific discoveries, contractual restrictions, creditor priorities, patient protection, and regulatory authorization.

The central lessons are:

For insolvency professionals: preserve asset value, investigate ownership, follow the applicable sale procedure, and protect creditor interests.

For purchasers: conduct intellectual-property and regulatory due diligence, identify assumed liabilities, and verify that the acquired assets can lawfully be used.

For creditors: investigate potentially preferential, undervalued, or fraudulent transactions where the evidence supports a challenge.

For research participants and regulators: recognize that the sale of a business does not automatically extinguish privacy, consent, biosafety, or regulatory obligations.

The Indian authorities discussed above establish important general principles, but there is no single universal rule governing every distressed-biotech asset sale. The outcome depends on the facts, the transaction structure, the current regulations, and the specific rights attached to the assets.

Research note: Before relying on this discussion in litigation or a transaction, verify the latest statutory text, amendments, and full judgments. The cases above are not all biotechnology-specific precedents, and the comparative US authorities are persuasive illustrations rather than binding Indian law.